Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV
interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD)
were treated for 4 weeks with Saizen to compare the response between GHD children born
appropriate for gestational age (AGA) and those born small for gestation age (SGA) after 4
weeks of Saizen therapy.